盛景微(603375.SH):維納芯擬出資400萬元與無錫聚聯等創投基金共同增資參股無錫聚荷達
格隆匯3月28日丨盛景微(603375.SH)公佈,公司子公司維納芯科技(無錫)有限公司(以下簡稱“維納芯”)擬出資人民幣400萬元與無錫聚聯創業投資合夥企業(有限合夥)(以下簡稱“無錫聚聯”)等創投基金共同增資參股無錫聚荷達傳感科技有限公司(以下簡稱“目標公司”“無錫聚荷達”),本次投資完成後維納芯佔目標公司持股比例爲11.43%,不會導致公司合併報表範圍發生變更,資金來源爲自有資金。本次對外投資開展的業務主要爲智能傳感器的開發和應用,爲子公司維納芯業務拓展的主要方向之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.